Search
ACADIA Pharmaceuticals Inc
ACADAdd to Watchlist
21.230USD
-0.010-0.05%
Close 11-06 16:00（ET）
3.66BMarket Cap
9.53P/E TTM
Today
-0.05%
5 Days
+3.11%
1 Month
+7.55%
6 Months
-1.16%
Year to Date
-20.52%
1 Year
-1.94%
Key Figures
21.000Open
21.450High
143.93KVolume
9.53P/E TTM
20.23P/E Dynamic
--Dividend TTM
0.08%Turnover Ratio
21.240Prev. Close
20.590Low
3.04MTurnover
16.18P/E Static
2.64P/B
0.00%Div Yield TTM
27.44%ROA
30.96052wk High
0.05Volume Ratio
226.45MNet Profit
172.31MShares
2.2300EPS TTM
0.84Beta
37.32%ROE
18.39052wk Low
9.61%Amplitude
89.75%Gross Margin
3.66BMarket Cap
5.69Reward/Risk
2.43%Risk Rate
ACADIA Pharmaceuticals Inc's Score
0.02vs previous score
Forecast8.00
Financial Health9.35
Technical4.34
Valuation Dimensions7.60
Institutional Confidence10.00
Risk Assessment7.35
Media Coverage
Coverage Level
Very Low
Very High
Neutral
Analyst Rating
ACADIA Pharmaceuticals Inc Technical Analysis
Technical Indicators
Sell
Summary
Neutral
Moving Average
Neutral
ACADIA Pharmaceuticals Inc Latest Earnings Call Transcripts
Acadia Pharmaceuticals (ACAD) Q3 2026 Earnings Call: DAYBUE Guidance Raised
Acadia Pharmaceuticals Q3 2026 earnings call: revenue rose 22% to $342 million, DAYBUE guidance increased, and remlifanserin advances to Phase III.
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q3
Earnings / Forecast
0.31/0.20
Revenue / Forecast
342.29M/332.47M
ACADIA Pharmaceuticals Inc Profile
SectorBiotechnology & Medical Research
Ticker SymbolACAD
Number of employees653
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| Baker Bros. Advisors LP | 25.05% |
| BlackRock Institutional Trust Company, N.A. | 10.77% |
| Vanguard Portfolio Management, LLC | 5.06% |
| State Street Investment Management (US) | 4.62% |
| Shareholder Types | Proportion |
|---|---|
| Hedge Fund | 35.20% |
| Investment Advisor | 32.87% |
| Investment Advisor/Hedge Fund | 25.77% |
| Research Firm | 1.93% |
Related Instruments
-0.79%
+1.43%
+1.07%
-0.14%
+0.38%
-0.22%
+0.03%
-0.41%
+0.02%
-0.20%
+0.85%
-1.57%
-1.04%
+0.28%
+5.27%
-0.16%
+0.16%
-0.80%
+1.46%
+3.63%Popular Instruments
51290.600
-208.500 (-0.41%)
26964.500
+329.300 (+1.24%)
7380.000
+23.100 (+0.31%)
12797.000
-1.000 (-0.01%)
58142.000
+876.000 (+1.53%)
6140.600
-37.200 (-0.60%)
89.857
-0.176 (-0.20%)
342.370
-1.800 (-0.52%)
186.640
+5.040 (+2.78%)
4065.670
-33.020 (-0.81%)
FAQs
What is the current price of ACADIA Pharmaceuticals Inc (ACAD)?
The current price of ACADIA Pharmaceuticals Inc (ACAD) is 21.23.
What is the symbol of ACADIA Pharmaceuticals Inc?
The ticker symbol of ACADIA Pharmaceuticals Inc is ACAD.
What is the 52-week high of ACADIA Pharmaceuticals Inc?
The 52-week high of ACADIA Pharmaceuticals Inc is 30.96.
What is the 52-week low of ACADIA Pharmaceuticals Inc?
The 52-week low of ACADIA Pharmaceuticals Inc is 18.39.
What is the market capitalization of ACADIA Pharmaceuticals Inc?
The market capitalization of ACADIA Pharmaceuticals Inc is 3.66B.
Is ACADIA Pharmaceuticals Inc (ACAD) currently rated as Buy, Hold, or Sell?
According to analysts, ACADIA Pharmaceuticals Inc (ACAD) has an overall rating of Buy, with a price target of 30.42.
What is the Earnings Per Share (EPS TTM) of ACADIA Pharmaceuticals Inc (ACAD)?
The Earnings Per Share (EPS TTM) of ACADIA Pharmaceuticals Inc (ACAD) is 2.23.